PLR、NLR在非小细胞性肺癌中的研究现状  

The Current State of Research on PLR and NLR in Non-Small Cell Lung Cancer

作　　者：米洵宇 向明钧[1] 向志 

机构地区：[1]吉首大学医学院,湖南 吉首 [2]吉首大学第四临床医学院,湖南 怀化

出　　处：《临床医学进展》2023年第12期19225-19229,共5页Advances in Clinical Medicine

摘　　要：肺癌在中国是致命性最高的恶性肿瘤之一,根据2015年中国癌症中心的数据,非小细胞性肺癌(NSCLC)占其中的85%。传统的诊断方式,如病理活检和PET-CT,虽然精确但不便于重复使用,且费用较高。近年来,炎症被认为是肿瘤发展的一个关键标志。特定的炎症指数,如中性粒细胞/淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR),已成为研究焦点。这些指标来自常规血常规,不仅费用低廉,而且方便多次测量。本文对NLR和PLR在NSCLC的诊断、分期和预后中的研究现状进行综述,可以为NSCLC的诊疗提供新的视角。Lung cancer is one of the most lethal malignancies in China, and according to data from the Chinese Cancer Center in 2015, non-small cell lung cancer (NSCLC) accounts for 85% of these cases. Tradi-tional diagnostic methods such as pathological biopsy and PET-CT, although accurate, are inconven-ient for repeated use and carry a high cost. In recent years, inflammation has been recognized as a key indicator of tumor development. Specific inflammatory indices, such as the neutro-phil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), have become a focus of research. These indices, derived from routine blood counts, are not only cost-effective but also con-venient for frequent testing. This article provides a review of the current research status of NLR and PLR in the diagnosis, staging, and prognosis of NSCLC, offering a new perspective for the diagnosis and treatment of NSCLC.

关 键 词：非小细胞性肺癌 炎症指标 诊断 预后 

分 类 号：R73[医药卫生—肿瘤]